A randomized, double-blind, placebo-controlled trial of Tomivosertib in combination with anti-PD-(L)1 therapy in subjects with non-small cell lung cancer as first-line therapy or when progressing on single-agent first-line anti-PD-(L)1 therapy. (eFT508-0011)
Cohort B is open: this is for patients with St. IIIB/St. IV NSCLC who are eligible for single-agent pembrolizumab for advanced/metastatic NSCLC in accordance with the package insert and have tumor PD-L1 >50% by 22C3 IHC.
STAR TRIALS CURRENTLY AVAILABLE – #20139, #21318, #21498, #22123, #22198, #20412